Beauty Device Brands Take Heed: Ulthera Fraud Suit Rooted In ‘FDA-Approved’ Versus ‘FDA-Cleared’
This article was originally published in The Rose Sheet
Executive Summary
The terms “FDA-approved” and “FDA-cleared” are not interchangeable; rather they denote distinct premarket regulatory pathways for medical devices with differing levels of FDA endorsement. Merz’s Ulthera unit recently failed to dismiss a false-advertising class action challenging its “FDA-approved” claims on an ultrasound system used in clinical settings for line and wrinkle treatment.
You may also be interested in...
Merz lifts aesthetics unit with $600m Ulthera takeover
German pharmaceutical firm Merz is expanding its aesthetics business with the agreed acquisition of Ulthera, a company specializing in non-surgical skin lifting, for up to $600m. The deal would mark Merz’s largest purchase in its history. It also illustrates an increasing interest from pharma companies in aesthetics, following Valeant’s hostile $54bn bid for Botox developer Allergan – the latter has so far resisted its rival’s overtures.
Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat
Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.
L’Oreal Joins J&J And Major Retailers Defending Benzene Class Actions In Federal Courts
Benzoyl peroxide-based acne drug products and their alleged proclivity to become contaminated with carcinogenic benzene are at the center of putative class actions filing against L’Oreal in federal courts around the US.